Pfizer Inc (PFE)
Profitability ratios
Return on sales
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross profit margin | 65.57% | 59.10% | 48.57% | 51.33% | 51.32% | 56.91% | 67.93% | 66.84% | 65.35% | 65.11% | 61.75% | 60.31% | 62.00% | 65.17% | 70.88% | 76.21% | 78.79% | 79.86% | 79.94% | 79.94% |
| Operating profit margin | 23.43% | 16.85% | 2.84% | 3.58% | 6.48% | 17.24% | 32.73% | 38.93% | 40.36% | 38.15% | 33.70% | 28.64% | 25.19% | 20.61% | 19.43% | 18.51% | 18.38% | 26.59% | 26.28% | 26.90% |
| Pretax margin | 12.61% | 6.49% | -7.48% | -3.25% | 1.81% | 15.20% | 29.21% | 34.37% | 34.61% | 33.37% | 31.74% | 29.51% | 29.40% | 29.29% | 25.53% | 23.89% | 21.39% | 17.48% | 34.67% | 34.04% |
| Net profit margin | 12.60% | 7.09% | -4.67% | -0.54% | 3.64% | 15.28% | 27.55% | 31.25% | 31.27% | 29.81% | 28.92% | 26.97% | 26.97% | 27.66% | 23.06% | 22.22% | 20.22% | 17.89% | 28.84% | 31.08% |
Based on the provided data, Pfizer Inc's profitability ratios have shown fluctuations over the analyzed periods.
1. Gross Profit Margin: Pfizer's gross profit margin has seen a decline from around 80% in early 2020 to about 50% by the end of 2024. This may indicate challenges in maintaining profitability on sales after deducting the cost of goods sold.
2. Operating Profit Margin: The operating profit margin initially decreased but then showed improvement, reaching a peak around mid-2022 before declining again. The wide fluctuations suggest changes in operational efficiency and cost management.
3. Pretax Margin: Pfizer's pretax margin experienced significant volatility, with a sharp decline in late 2023 and early 2024, indicating challenges in generating profits before accounting for taxes.
4. Net Profit Margin: The net profit margin also displayed fluctuations, with a notable decrease in late 2023 and early 2024. This could imply variability in Pfizer's ability to generate profits after all expenses, including taxes.
Overall, Pfizer's profitability ratios reflect a mix of challenges and improvements in managing costs, generating revenues, and sustaining profitability over the analyzed periods. Further analysis would be needed to understand the specific drivers behind these fluctuations and assess Pfizer's overall financial health.
Return on investment
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating return on assets (Operating ROA) | 6.99% | 4.62% | 0.73% | 0.89% | 1.67% | 5.50% | 11.59% | 18.50% | 20.53% | 19.51% | 17.49% | 14.42% | 11.31% | 7.98% | 6.56% | 5.85% | 5.68% | 7.23% | 7.27% | 8.19% |
| Return on assets (ROA) | 3.76% | 1.94% | -1.20% | -0.13% | 0.94% | 4.87% | 9.75% | 14.85% | 15.91% | 15.24% | 15.01% | 13.58% | 12.11% | 10.70% | 7.78% | 7.02% | 6.25% | 4.86% | 7.97% | 9.47% |
| Return on total capital | 12.60% | 7.52% | -1.38% | 1.24% | 3.95% | 12.90% | 24.71% | 32.86% | 37.60% | 37.31% | 38.31% | 34.70% | 31.49% | 23.68% | 18.60% | 13.84% | 12.08% | 13.48% | 25.91% | 27.38% |
| Return on equity (ROE) | 9.09% | 4.62% | -2.96% | -0.32% | 2.40% | 10.80% | 21.68% | 28.77% | 32.79% | 32.14% | 33.61% | 30.29% | 28.47% | 25.34% | 18.89% | 16.25% | 15.23% | 13.33% | 22.05% | 24.21% |
Pfizer Inc's profitability ratios show varying trends over the reporting period.
- Operating return on assets (Operating ROA) increased steadily from March 31, 2020, to December 31, 2022, peaking at 20.53%. However, it declined thereafter, reaching 4.62% by December 31, 2024.
- Return on assets (ROA) followed a similar pattern, with an upward trend until December 31, 2022, before decreasing to 3.76% by December 31, 2024.
- Return on total capital fluctuated but generally showed an increasing trend until December 31, 2022. It stood at 12.60% by December 31, 2024.
- Return on equity (ROE) displayed a consistent increase from March 31, 2020, to December 31, 2022, peaking at 32.79%. However, it declined by the end of the period to 9.09% by December 31, 2024.
Overall, Pfizer Inc's profitability ratios indicate a strong performance in the earlier years, with some decline in profitability towards the end of the reporting period, potentially signaling challenges or changes in the company's operations or market conditions.